Immunological markers for predicting the response to immunotherapy in non-small cell lung cancer

Itroduction. Immune checkpoint inhibitors have become the standard of care for patients with advanced non-small cell lung cancer. However, despite the determination of programmed death-ligand 1 expression in clinical practice, which determines the effectiveness of therapy, up to 80 % of patients with non-small cell lung cancer do not respond to treatment.

The study objective – investigation of the prognostic role of clinical and immunological markers during immune checkpoint inhibitor monotherapy in ≥2 lines in patients with advanced non-small cell lung cancer.

Materials and methods. The study included 45 patients with advanced non-small cell lung cancer receiving programmed cell death 1 / programmed death-ligand 1 inhibitors in monotherapy in 2 and subsequent lines (Group 1), as well as 30 patients with advanced non-small cell lung cancer receiving first-line chemotherapy (Group 2). All patients from 2 groups did not have autoimmune diseases before starting treatment. The determination of autoantibodies, β-2-microglobulin, neopterin, interleukin 6, interleukin 18 and the allelic variant of HLA-DRB1 in patients in the Group 1 was carried out 2 months after the start of therapy, and in the Group 2 – before the start of the next chemotherapy cycle.

Results. In Group 1, the presence of EGFR / ALK mutations is an independent predictor of shorter progression-free survival (p = 0.018). Also, in the univariate analysis, neutrophil-lymphocyte ratio <5 before immune checkpoint inhibitors (p = 0.009) and the appearance of immune-related adverse events (p = 0.038) are associated with long-term progressionfree survival. In Group 1, β-2-microglobulin was lower in patients with a response duration of ≥6 months than with a progression <6 months: 1.7 mg / L and 2.9 mg / L, respectively (p <0.0001). Patients receiving immune checkpoint inhibitors with a β-2-microglobulin level ≥2.5 mg / L have a shorter progression-free survival than patients with a marker value <2.5 mg / L: 168 days and the value is not reached, respectively (p = 0.017). In response duration ≥6 months neopterin value was lower than in disease progression: 8.6 nmol / l and 13.4 nmol / L, respectively (p <0,0001). Progression-free survival was lower in patients with neopterin ≥12 nmol / L than patients with neopterin <12 nmol / L: median was 164 days and the value was not reached, respectively (p = 0.0007). Based on the results of multivariate analysis, β-2-microglobulin ≥2.5 mg / L (p = 0.006) and neopterin ≥12 nmol / L (p = 0.027) were independent predictors of shorter progression-free survival. Low levels of interleukin 6 and interleukin 18, as well as antibodies to thyroperoxidase, are associated with a response of ≥6 months. HLA-DRB1*03 was associated with a duration of response of ≥6 months, as well as a longer progression-free survival compared with other allelic variants. The levels of β-2-microglobulin, neopterin, interleukin 6, interleukin 18 were higher in patients in Group 1 than in patients in Group 2 (p <0.0001).

Conclusion. Immunological markers can serve as promising prognosis markers in patients with advanced non-small cell lung cancer during immunotherapy.

1. Bai R., Lv Z., Xu D., Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res 2020;8:34. DOI: 10.1186/s40364-020-00209-0.

2. Pourmir I., Gazeau B., de Saint Basile H., Fabre E. Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality? Cancer Drug Resist 2020;3:276–86. DOI: 10.20517/cdr.2020.14.

3. Möller M., Turzer S., Schütte W. et al. Blood immune cell biomarkers in patient with lung cancer undergoing treatment with checkpoint blockade. J Immunother 2020;43(2):57–66. DOI: 10.1097/CJI.0000000000000297.

4. Salmaninejad A., Valilou S.F., Shabgah A.G. et al. PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol 2019;234(10):16824–37. DOI: 10.1002/jcp.28358.

5. Reck M., Rodríguez-Abreu D., Robinson A.G. et al. Pembrolizumab versus chemotherapy for PD-L1 – positive non–small-cell lung cancer. N Engl J Med 2016;375(19):1823–33. DOI: 10.1056/NEJMoa1606774.

6. Duchemann B., Remon J., Naigeon M. et al. Integrating circulating biomarkers in the immune checkpoint inhibitor treatment in lung cancer. Cancers (Basel) 2020;12(12):3625. DOI: 10.3390/cancers12123625.

7. Wang L., Hu Y., Wang S. et al. Biomarkers of immunotherapy in non-small cell lung cancer. Oncol Lett 2020;20(5):139. DOI: 10.3892/ol.2020.11999.

8. Prelaj A., Tay R., Ferrara R. et al. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer 2019;106:144–59. DOI: 10.1016/j.ejca.2018.11.002.

9. Zhang H., Cui B., Zhou Y. et al. B2M overexpression correlates with malignancy and immune signatures in human gliomas. Sci Rep 2021;11:5045. DOI: 10.1038/s41598-021-84465-6.

10. Xie J., Wang Y., Freeman M.E. et al. β2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood 2003;101(10):4005–12. DOI: 10.1182/blood-2002-11-3368.

11. Melichar B., Spisarová M., Bartoušková et al. Neopterin as a biomarker of immune response in cancer patients. Ann Transl Med 2017;5(13):280. DOI: 10.21037/atm.2017.06.29.

12. Keegan A., Ricciuti B., Garden P. et al. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer 2020;8:e000678. DOI: 10.1136/jitc-2020-000678.

13. Hussaini S., Chehade R., Boldt R.G. et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis. Cancer Treat Rev 2021;92:102134. DOI: 10.1016/j.ctrv.2020.102134.

14. Basak E.A., van der Meer J.W.M., Hurkmans D.P. et al. Overt thyroid dysfunction and anti-thyroid antibodies predict response to anti-PD-1 immunotherapy in cancer patients. Thyroid 2020;30(7):966–73. DOI: 10.1089/thy.2019.0726.